Company info:

  • 1-50
  • 2020
  • Boston, MA
  • 100-500M

Claim company profile

About company:

GentiBio is developing engineered regulatory T cells (Tregs). Tregs are the body’s natural means for keeping the immune system in balance. Tregs suppress potentially pathogenic immune activation and promote tissue repair; however, Treg activity is lost in some diseases. GentiBio is using their modular engineering platform to create optimized Tregs as powerful and tailored therapeutics for autoimmune and inflammatory diseases.

GentiBio’s engineered Tregs overcome the limitations of endogenous, sorted Tregs by transforming the cells with superior phenotypes including resistance to inflammation, increased potency and scalable manufacturing. GentiBio’s most advanced product is GNTI-122, an autologous engineered Tregs product to treat type 1 diabetes.


Scientist/Senior Scientist, Discovery Immunology
Boston, MA|100+ days ago
Associate Scientist/Senior Associate Scientist, Di...
Boston, MA|100+ days ago

© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy